Thank you Yonah. Good morning everyone and thank you for joining us. Before I discuss the business highlights, I would like to comment briefly on the three unsolicited proposals we received in recent months from Nano Dimension to acquire Stratasys initially for $18.00, then $19.55, and subsequently for $20.05 per share in cash. As previously announced, consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, the Stratasys board carefully reviewed and evaluated each proposal. Following each review, the Stratasys board unanimously rejected all three proposals because they each substantially undervalued Stratasys in light of the company’s standalone prospects. As we have articulated previously, Nano is in the midst of multiple lawsuits with its shareholders involving the controlling governance of the company and, as a result, serious questions remain about the legal legitimacy of the Nano offer. The Stratasys board and management team are committed to enhancing shareholder value and continue to successfully execute on the company’s growth strategy. We are making strong progress towards becoming a highly profitable $1 billion revenue company. As part of its fiduciary duties, the board will review any bona fide proposal for the company and weigh it against our standalone plan. We are not going to comment further on this matter today. We appreciate you keeping your questions focused on our results as the focus of this call is our performance for the quarter. Our excellent results for Q1 2023 represent another consecutive quarter of solid performance, despite an increasingly challenging macro backdrop. We continue to execute on our winning strategy driven by our broad global and diverse set of systems, materials and software solutions. With our leadership position, our five key technologies, resilient business model and strong financial profile, we believe we are positioned to accelerate growth and drive shareholder returns not only for today but also for years to come. Our confidence is reflected in the medium term focus we are announcing today. Eitan will provide further details during his remarks, but we expect to surpass $1 billion in revenue in 2026 with substantial profitability. In terms of our first quarter results, we are seeing stronger utilization by our customers than ever before, which drove all-time record revenues in both consumables and customer service. As we have noted in the past few earnings calls, macro related pressure on capex budgets are causing longer sales cycles and occasional deferrals of orders. Our OEM revenue was relatively flat to the first quarter of last year, adjusted for FX and divestments, primarily due to the impact of those factors on hardware purchases. The manufacturing trend of on-shoring, de-globalization and just-in-time production are driving opportunities for growth. Stratasys is positioned to take advantage of these opportunities give our combination of proven market leading systems in FDM and polyjet, new technology offerings in P3, sub and stereolithography, the broadest set of polymer materials in the industry, a unified software platform across the portfolio, and unmet go-to-market capabilities. Along with our robust balance sheet, this sets us apart and will enable us to sustain organic growth and expand our reach via the pursuit of external opportunities. Engagement with both our installed base and new customers remains strong. We continue to expand our customer reach across our entire suite of technologies, particularly targeting manufacturing applications. We have demonstrated a resilience and recurring business model that delivered gross margins this quarter that were flat compared to the year-ago period, and also kept opex spending as a percentage of revenue nearly flat to the corresponding period last year even with a reduction in revenue. As a result of our efforts and despite the headwinds faced, I’m proud that we delivered positive adjusted earnings per share for the seventh consecutive quarter. Our vision for the future of additive manufacturing and in turn our ability to deliver greater returns for our shareholders is more robust than ever. We ended the quarter with a strong balance sheet that includes no debt and $288 million in cash and equivalents. This continues to support our growth through organic investments and accretive acquisition opportunities, including early stage but highly compelling technology-driven businesses which we believe will improve results as we leverage our infrastructure and experience to strengthen operations. Now let me turn to the exciting achievements and milestones reached since the end of 2022. In February, we introduced monolithic multi-colored 3D printer dental solution through our TrueDent resin, our first-ever FDA cleared medical device. As a reminder, dental overall is a $50 billion TAM and is a fast growing industry for additive manufacturing. The TrueDent solution enables labs to create permanent natural looking dentures with accurate tooth structures, gum shade and translucency in one continuous print. The resin is designed for exclusive use in our J5 DentaJet printers using GrabCAD print software and provides dental labs the ability to scale manufacturing with simplified work flow and reduced processing time to deliver the best quality dentures available in the market today. We already have several new customers and many of the largest dental labs are actively evaluating the solution. In February, we launched the new J3 DentaJet printer, opening up more opportunities for Stratasys such as implant models and surgical guides for dental labs. It recently received an excellent reception at the dental industry’s largest trade show. Our superior accuracy provides an entry point for customers ready to step up from lower quality solutions. One of the world’s largest dental labs said it tripled its daily production volume with the J3 relative to the previous system. Moving to our medical highlights, in February we signed an agreement with Ricoh USA to provide on-demand 3D printed anatomic models for clinical settings. Our patient-specific 3D printed solutions combine our 3D printing technology, the cloud-based segmentation as a service solution from Axial3D, and precision additive manufacturing service from Ricoh into one convenient solution. This represents an expansion of the relationship between Ricoh 3D for healthcare and Stratasys. After quarter end, we forged a joint development and commercialization agreement with CollPlant Biotechnologies to transform healthcare with industrial-scale bio printing of tissues and organs. The initial focus of the relationship will be around development of bio printing solutions for CollPlant’s regenerative breast implants, a $2.6 billion opportunity. Further, the combination of our P3 technology-based bio printer with their RH collagen-based bio ink is also ideal for future innovation and production of additional human tissues and organs. Both companies agreed to cross-promote our respective bio printing products. On the industrial side, in March we secured a multi system opportunity with Götz Maschinenbau for our mass production H350 printers. The sale involved four additional systems to help the German Service Bureau meet growing demand for high quality end use parts. Götz is already a valued partner that also deploys FDM and polyjet-based Stratasys printers. In addition, in early April we closed the acquisition of Covestro’s additive manufacturing materials business which expands our differentiated 3D printed material offering in stereolithography, DLP and powders to address more manufacturing industry applications. Covestro is expected to be immediately accretive and includes R&D facilities, global development and sales teams, and a portfolio of 60 materials for additive manufacturing. Together, we will be able to address more applications faster, pushing the boundaries of what is possible in additive manufacturing. We are also growing our focus on adding value for customers while increasing recurring revenue through significant software announcements. Last month, we introduced GrabCAD Print Pro, which provides a major productivity boost for our customers. The initial rollout is for our SAF and FDM systems, applicable for end use parts and production scale volume, tooling and prototypes. We plan to make this software update available across our other three technologies as well. The annual subscription package includes quality management capabilities from our recent acquisition as well as added functionality from third party partners. Three value-add plug-in partners available in the initial release as we continue growing our ecosystem are Castor, AlphaSTAR, and Cognitive Design Systems. These advances in software are helping Stratasys integrate into scaled up industry 4.0 infrastructure. In fact, the Advanced Manufacturing Research Center at the University of Sheffield has been able to successfully incorporate Stratasys’ data into its factory-plus architecture right alongside CNC machines, robot arms and other mainstream factory equipment. In addition, Stratasys’ expansion into software is helping drive opportunities with systems and materials. Our previously announced OpenAM software is now widely available to customers and we are seeing it help unlock Fortus 450 printer opportunities with manufacturing customers that are interested in FDM for end use part applications due to the greater flexibility it provides in material selection. That is also a key driver of customers’ interest in Origin One printers as well. Our technological innovations, best-in-class sales channels, and key partnerships are contributing to our efforts to build on our meaningful foundations for growth that will drive our industry leadership for the long term. I will now turn the call over to our CFO, Eitan